Key Highlights

  • SYK shares fell 5.87% today to $327.62, down from a prior close of $348.04.
  • Q2 adjusted EPS of $3.69 beat the $3.49 estimate, but revenue of $6.59 billion came in merely in line with consensus.
  • The company narrowed full-year adjusted EPS guidance slightly higher to $14.95-$15.10, with organic sales growth guidance of 8.3%-9.3%.
  • Several sell-side analysts trimmed price targets, including JPMorgan (to $350), Jefferies (to $440) and Piper Sandler (to $390), even while maintaining bullish ratings.

In-Line Revenue Overshadows EPS Beat

Stryker (NYSE:SYK) shares are sliding roughly 6% today as investors react to second-quarter results reported Thursday evening that beat on adjusted EPS but showed revenue merely in line with consensus. Stryker, headquartered in Portage, Michigan, is a leading global medical technology company operating through two core segments, Orthopaedics and Spine, and MedSurg and Neurotechnology, with a product portfolio spanning joint replacement implants, surgical navigation systems and neurovascular devices.

Adjusted EPS of $3.69 beat the $3.49 estimate, up 17.9% year-over-year, as the company continued recovering from a March cyberattack that disrupted first-quarter production, with U.S. organic growth of 9% and international organic growth of 8.9%. Despite the beat, the stock's selloff also comes amid a broader mixed reaction across medical device peers reporting this week, with DexCom (NASDAQ:DXCM) surging on its print while Merit Medical soared, suggesting investors are scrutinizing profitability and tariff-related cost pressures across the sector.

Peripheral Vascular Disruption and Narrowed Guidance

Stryker carries a market capitalization of approximately $125.60 billion, with shares trading at a trailing price-to-earnings ratio of 24.47 and a dividend yield of 1.06%. The stock's 52-week range spans $281.00 to $396.86.

The company's Peripheral Vascular business saw a 6.7% organic sales decline due to a supply disruption at a key plant, causing backorders and lost sales, though management expects backorders to reach manageable levels by the end of the third quarter with a return to double-digit growth expected as the AVS acquisition, including IVL technology, integrates. The company narrowed full-year 2026 guidance to organic net sales growth of 8.3%-9.3% and adjusted EPS of $14.95-$15.10, raising the low end of both ranges.

Several sell-side analysts trimmed price targets following the print, including JPMorgan (to $350 from $400), Jefferies (to $440 from $455), Piper Sandler (to $390 from $420), and RBC (to $420 from $435), even while maintaining bullish ratings, suggesting growth-trajectory concerns rather than a fundamental change in outlook. Adjusted gross margin was 66%, up 60 basis points year-over-year, and adjusted operating margin reached 27.4%, up 170 basis points, with the company reaffirming its multi-year target of 150 basis points of cumulative operating margin improvement over three years.

Conclusion

Stryker's decline despite an EPS beat reflects investor focus on merely in-line revenue and the ongoing Peripheral Vascular supply disruption, even as the company continues recovering from its March cyberattack and narrows full-year guidance modestly higher. With several analysts trimming price targets while maintaining bullish ratings, investors will be watching for confirmation that the AVS integration and backorder resolution support a return to stronger growth in the second half of the year.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.